Icariin inhibits proliferation and migration of VSMCs via LncRNA H19 competitively binding to HuR
7.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-01 04:00
摘要：
Icariin, a bioactive compound from traditional Chinese medicine, has been shown to inhibit the proliferation and migration of vascular smooth muscle cells (VSMCs) through the regulation of lncRNA H19. This study elucidates the molecular mechanism by which lncRNA H19 interacts with HuR, affecting the stability of mRNAs related to cell cycle regulation, particularly cyclin D1 and MMP-9. The findings suggest that icariin could be a promising therapeutic agent for managing atherosclerosis, highlighting its potential in cardiovascular disease treatment.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分+1.0分
business_impact
0.5分+0.5分
scientific_rigor
1.5分+1.5分
timeliness_innovation
1.5分+1.5分
investment_perspective
2.5分+2.5分
market_value_relevance
1.0分+1.0分
team_institution_background
0.5分+0.5分
technical_barrier_competition
0.7分+0.7分
关键证据
Icariin inhibits proliferation and migration of HA-VSMCs.
LncRNA H19 serves as an endogenous competing RNA to disable HuR.
Research provides a novel molecular mechanism of ICA in atherosclerosis treatment.
真实性检查
否
AI评分总结
Icariin, a bioactive compound from traditional Chinese medicine, has been shown to inhibit the proliferation and migration of vascular smooth muscle cells (VSMCs) through the regulation of lncRNA H19. This study elucidates the molecular mechanism by which lncRNA H19 interacts with HuR, affecting the stability of mRNAs related to cell cycle regulation, particularly cyclin D1 and MMP-9. The findings suggest that icariin could be a promising therapeutic agent for managing atherosclerosis, highlighting its potential in cardiovascular disease treatment.